Company: EDSA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001171843-25-003189
Chunk: 62

Company: Edesa Biotech, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 62
---
61,858,769
			)
			 
			$
			15,539,598

			Six Months Ended March 31, 2024

			Balance - September 30, 2023

			3,075,473

			$
			46,643,151

			$
			-

			$
			-

			$
			13,039,265

			$
			(214,648
			)
			 
			$
			(52,418,968
			)
			 
			$
			7,048,800

			Issuance of common shares

			140,495

			590,966

			-

			-

			-

			-

			-

			590,966

			Issuance costs

			-

			(97,949
			)

			-

			-

			-

			-

			-

			(97,949
			)

			Share-based compensation

			-

			-

			-

			-

			334,053

			-

			-

			334,053

			Net loss and comprehensive loss

			-

			-

			-

			-

			-

			(11,755
			)

			(3,539,782
			)

			(3,551,537
			)

			Balance - March 31, 2024

			3,215,968

			$
			47,136,168

			$
			-

			$
			-

			$
			13,373,318

			$
			(226,403
			)
			 
			$
			(55,958,750
			)
			 
			$
			4,324,333

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

6

Edesa Biotech, Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

1. Nature of Operations

Edesa Biotech, Inc. (the “Company” or “Edesa”) is a biopharmaceutical company focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The Company is organized under the laws of British Columbia